Expected improvements in results

Expected changes when switching from dolutegravir (DTG) to raltegravir (RAL)

Below is an evidence-based look at clinical parameters that might change when moving from DTG to RAL. Where available, head-to-head data (e.g., SPRING‑2) and large cohort/pooled analyses are prioritized.

Liver enzymes (ALT/AST)

• Both DTG and RAL have low rates of clinically significant hepatotoxicity; RAL has “not been linked convincingly” to aminotransferase elevations, while DTG is associated with a low rate of elevations and rare clinically apparent injury.ncbi.nlm.nih+1
• Large contemporary cohort work focused on chronic liver enzyme elevation (cLEE) did not identify safety concerns with integrase inhibitors (including DTG and RAL); increased cLEE risk was more associated with NNRTIs (especially efavirenz, rilpivirine) and TDF, with a nonsignificant trend toward reduced cLEE on TAF.academic.oup
• In DTG vs RAL trials, grade 3/4 ALT/AST abnormalities were infrequent and similar between arms; no signal that RAL materially improves ALT over DTG in virologically suppressed patients was shown.natap+1

Takeaway: A consistent ALT drop attributable to switching from DTG to RAL is not well supported; both are generally liver-safe, and background agents (e.g., TDF vs TAF) and comorbid hepatitis often drive ALT trends.ncbi.nlm.nih+2

Weight and “brain fog”/CNS symptoms

• Weight: Integrase inhibitors as a class can be associated with weight gain. Observational data show DTG and RAL regimens both gained more weight than elvitegravir; DTG tended to gain more than NNRTIs and some PIs, and was similar to RAL at many time points, though some analyses found steeper BMI trajectories with DTG than RAL.i-base+1
• CNS symptoms: Neuropsychiatric events (insomnia, abnormal dreams, mood symptoms) have been reported with DTG at low rates; discontinuations due to CNS events were under 5% in trials and often lower than efavirenz, but signals exist, particularly in older age or with abacavir backbones in some cohorts.aidsmap+1

Takeaway: If weight gain has been prominent on DTG, a switch to RAL may modestly attenuate further gain in some individuals, but RAL is not clearly weight‑neutral and weight gain has been observed with RAL too. For “brain fog,” individual patients who experience DTG‑linked sleep or mood issues sometimes report improvement after switching off DTG; although direct DTG→RAL reversal data are limited, improvement after switching from DTG to other non‑DTG regimens has been documented.pmc.ncbi.nlm.nih+3

Lipids

• Comparative analyses show DTG and RAL have broadly similar, generally minimal effects on total cholesterol, LDL‑C, HDL‑C, and triglycerides in treatment‑naive settings, and are more lipid‑friendly than efavirenz or boosted PIs.pmc.ncbi.nlm.nih+2
• Randomized head‑to‑head (SPRING‑2) reported no clinically significant fasting lipid changes over time in either DTG or RAL arms.natap

Takeaway: A meaningful lipid improvement purely from switching DTG→RAL is unlikely; both have favorable, similar lipid profiles relative to many alternatives.journals.plos+2

Renal markers (serum creatinine, eGFR/GFR)

• DTG inhibits tubular creatinine secretion via OCT2/MATE2‑K, raising serum creatinine and lowering eGFR estimates without changing true GFR; this small increase typically occurs in the first 2–3 weeks and plateaus.pmc.ncbi.nlm.nih+2
• In SPRING‑2, mean creatinine rose more with DTG than RAL (≈12.3 vs 4.7 µmol/L at 48 weeks), with larger apparent declines in creatinine clearance on DTG; these changes reflect assay/transport effects, not true GFR loss, and were not associated with renal adverse events.aidsmap+2

Takeaway: On switching from DTG to RAL, expect a small decrease in serum creatinine and corresponding increase in estimated eGFR (i.e., reversal of DTG’s transporter effect), without true change in glomerular function.pmc.ncbi.nlm.nih+2

Practical expectations by outcome

• Lowering ALT: Not reliably expected from DTG→RAL alone; both have low hepatotoxicity. Consider other contributors (hepatitis coinfection, alcohol, concomitant drugs, TDF vs TAF) if ALT is elevated.ncbi.nlm.nih+2
• Weight loss: Not expected as a class effect; RAL can still be associated with weight gain, though some cohorts suggest DTG may have slightly greater gain than RAL. Any weight change after switching is variable and patient‑specific.i-base+1
• Less brain fog/better sleep: Possible in individuals who experienced DTG‑associated neuropsychiatric effects; case series and trials show sleep/mood improvements after switching off DTG, though not specifically to RAL in most reports.pmc.ncbi.nlm.nih+1
• Improved lipids: Unlikely to change meaningfully; DTG and RAL have similar and generally favorable lipid effects relative to many other agents.pmc.ncbi.nlm.nih+2
• Improved eGFR/lowered creatinine: Likely a small improvement in estimated eGFR and a small drop in serum creatinine reflecting removal of DTG’s OCT2/MATE effect; true GFR typically unchanged.pmc.ncbi.nlm.nih+2

Key citations

• Liver enzyme safety for DTG and RAL: LiverTox summaries and RESPOND cohort cLEE analysis.ncbi.nlm.nih+2
• Weight: INSTI weight gain patterns including DTG and RAL; DTG steeper BMI slopes than RAL in some analyses.pmc.ncbi.nlm.nih+1
• CNS: Low overall trial discontinuation but documented DTG‑associated sleep/mood symptoms and improvement after switching off DTG.aidsmap+1
• Lipids: Comparative analyses showing similar minimal lipid impact for DTG and RAL; SPRING‑2.journals.plos+2
• Renal markers: DTG’s OCT2/MATE‑mediated creatinine rise and head‑to‑head creatinine differences vs RAL; true GFR unaffected.pmc.ncbi.nlm.nih+3